Although BTK inhibitors were originally developed for B-cell malignancies, such as certain types of lymphomas and leukemias, they have been explored as potential treatments for MS due to their ability to modulate B-cell activity and other immune responses. The gene discussed is BTK; the disease is myeloid sarcoma.